DexCom, Inc. (NASDAQ:DXCM) Shares Sold by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. trimmed its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 30.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 38,412 shares of the medical device company’s stock after selling 16,619 shares during the quarter. PNC Financial Services Group Inc.’s holdings in DexCom were worth $2,575,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in DXCM. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in DexCom in the 3rd quarter valued at about $1,514,000. Banque Cantonale Vaudoise increased its stake in shares of DexCom by 169.8% in the third quarter. Banque Cantonale Vaudoise now owns 11,811 shares of the medical device company’s stock valued at $791,000 after purchasing an additional 7,433 shares during the period. Fifth Third Wealth Advisors LLC raised its holdings in shares of DexCom by 305.4% during the third quarter. Fifth Third Wealth Advisors LLC now owns 29,646 shares of the medical device company’s stock valued at $1,987,000 after buying an additional 22,334 shares during the last quarter. Swiss National Bank boosted its position in shares of DexCom by 3.4% during the third quarter. Swiss National Bank now owns 1,180,400 shares of the medical device company’s stock worth $79,134,000 after buying an additional 39,000 shares during the period. Finally, Thrivent Financial for Lutherans grew its holdings in DexCom by 44.2% in the 3rd quarter. Thrivent Financial for Lutherans now owns 314,102 shares of the medical device company’s stock worth $21,058,000 after buying an additional 96,274 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 5,431 shares of company stock valued at $399,319. 0.30% of the stock is owned by corporate insiders.

DexCom Stock Up 6.9 %

Shares of DexCom stock opened at $77.83 on Tuesday. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The firm has a market capitalization of $30.40 billion, a PE ratio of 46.60, a price-to-earnings-growth ratio of 2.23 and a beta of 1.17. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The stock’s fifty day moving average is $70.76 and its 200-day moving average is $88.93.

Wall Street Analyst Weigh In

Several analysts have weighed in on DXCM shares. Wells Fargo & Company lifted their target price on DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. Stifel Nicolaus raised their price target on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, August 23rd. Leerink Partners reduced their price objective on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Royal Bank of Canada lowered their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Finally, StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, DexCom presently has an average rating of “Moderate Buy” and an average target price of $104.59.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.